Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207876 | 0.85 | HDAC8 (0.34) | HDAC8CDC7CDK2CYP1A1CYP1B1 | |
| SCHEMBL209074 | 0.71 | BACE1 (0.38) | — | |
| SCHEMBL1450911 | 0.71 | MEN1 (0.38) | — | |
| SCHEMBL27773882 | 0.71 | PLAU (0.41) | — | |
| SCHEMBL208536 | 0.71 | NR4A2 (0.38) | — | |
| SCHEMBL208082 | 0.71 | BACE1 (0.38) | — | |
| SCHEMBL2358946 | 0.71 | CYP1A2 (0.42) | — | |
| SCHEMBL16289696 | 0.68 | CYP1A1 (0.38) | HDAC8CDC7CDK2CYP1A1CYP1B1 | |
| SCHEMBL1478481 | 0.67 | CYP1A1 (0.54) | HDAC8CDC7CDK2CYP1A1CYP1B1 | |
| SCHEMBL29870412 | 0.67 | CYP1A1 (0.54) | HDAC8CDC7CDK2CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088796-B2 | Triamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | disclosed |
| CN-101163700-A | Triamine derivative | DAIICHI SEIYAKU CO (JP) | 2008-04-16 | — | — | CN | disclosed |
| EP-1864982-A1 | TRIAMINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239857-A1 | TRIAMINE DERIVATIVE | F2, F12, F3 | HDAC8 1700/4885CDC7 3422/4885CDK2 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.